期刊文献+

奥美沙坦联合依那普利对高血压患者心功能及左心室肥厚的影响 被引量:3

Effects of combination Olmesartan with Enalapril on cardiac function and left ventricular hypertrophy in hypertension
下载PDF
导出
摘要 目的:探讨奥美沙坦联用依那普利对高血压患者心功能及左心室肥厚的影响。方法:60例高血压患者随机分为治疗组和对照组,每组患者30例,观察两组患者治疗前后的血压和心率变化情况,采用彩色超声心动图测定治疗前及治疗6个月后左心功能及左心室参数变化。结果:治疗6个月后,治疗组每搏输出量(SV)、每分输出量(CO)、左室射血分数(LVEF)均高于治疗前和对照组(P<0.05);左室收缩未期内径(LVSd)、左室舒张未期内径(LVDd)、左室心肌重量指数(LVMI)均下降,较治疗前及对照组减少,差异有统计学意义(P<0.05)。结论:奥美沙坦联用依那普利改善高血压患者心功能及左心室肥厚的作用优于单独应用依那普利。 Objective:To evaluate effects of combination Olmesartan with Enalapril on cardiac function and left ventricular hypertrophy(LVH) in hypertensive patients.Methods:60 patients with hypertension were randomly divided into treatment group and control group,and each group was 30 patients.Blood pressure and heart rate were examined every day.Cardiac function and LVH parameters were measured by the color ultrasonic cardiogram(UCG) before and after 6 months of treatment the patients.Results: The SV,CO and LVEF were increased significantly in the treatment group(P0.05).The LVDd,LVSd and LVMI were decreased significantly in the treatment group(P0.05).Conclusions: The combination of Olmesartan with Enalapril in hypertensive patients has better effect on left ventricular function and LVH than Enalapril alone.
作者 董书芳
出处 《中国民康医学》 2011年第21期2631-2633,共3页 Medical Journal of Chinese People’s Health
关键词 奥美沙坦 依那普利 高血压 心功能 左心室肥厚 Olmesartan Enalapril Hypertension Cardiac funct on Left ventricle hypertrophy
  • 相关文献

参考文献7

二级参考文献15

  • 1王宪衍,王孝铭,龚兰生,陆德澄,李俭春,杨培林,李明德,吴晔良.依那普利单用与合用氢氯噻嗪治疗原发性高血压的比较[J].新药与临床,1993,12(2):66-68. 被引量:14
  • 2刘志远,张金盈,张彦军,张力.高血压病患者左室肥厚与心率变异性的临床研究[J].中国心血管病研究,2006,4(9):646-648. 被引量:8
  • 3陈国伟主编.现代心脏内科学.第1版.长沙:湖南科学技术出版社,2000.343.
  • 4Schmieder RE,Martus P, Klingbeil A.Reversal of left ventricular hypertrophy in essential hypertension.A meta-analysis of randomized double-blind studies[J].JAMA, 1996,275(19): 1507-1513.
  • 5Gottdiener JS,Reda DJ,et al.Left atrial size in hypertensive men: influence of obesity, race and age.Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents[J].J Am Coll Cardiol, 1997,29(3):651-658.
  • 6Ju H,Cardiovase Res,1997年,35卷,223页
  • 7Yang B C,Circulation,1997年,96卷,922页
  • 8Liu Y H,J Clin Invest,1997年,99卷,1926页
  • 9Liao Y,Can J Cardiol,1995年,11卷,13F页
  • 10Kang P M,Am Heart J,1994年,127卷,1338页

共引文献46

同被引文献33

  • 1刘力生.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93. 被引量:1225
  • 2张亚文,丁茹,吴宗贵,陈琴珍,王丽娟.奥美沙坦酯治疗轻中度原发性高血压的疗效和安全性[J].世界临床药物,2006,27(10):585-589. 被引量:9
  • 3Laeis P,Puchler K, Kiech W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction[ J]. J Hypertens,2001,19 :S21-32.
  • 4Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin Ⅱ type Ⅰ receptor [ J ]. J Biol Chem,2006,281:19288-19295.
  • 5Miura S, Kiya Y, Kanazawa T, et al. Differential bonding interactions of inverse agonists of angiotensin Ⅱ typeⅠ receptor in stabilizing the inactive state[J]. Mol Endocrinol,2008 ,22 :139-146.
  • 6Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist[ J]. Am J Cardiol,2001,87 :37-43.
  • 7Reinhold K. Olmesartan/amlodipine: a review of its use in the management of hypertension[ J]. Vascular Health and Risk Man-agement,2011,7 : 183 - 192.
  • 8Oparil S, Williams D, Chrysant S, et al. Comparative efficacy of olmcsartan, losartan, valsartan and irbesartan in the control of essential hypertension[J]. J Clin Hypertens,2001,3 :283-291.
  • 9Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management : a European Society of Hypertension Task Force document [ J ]. J Hypertens, 2009, 27:2121-2158.
  • 10Ram CV. Antihypertensive efficacy of angiotensin receptor block- ers in combination with hydrochlorothiazide : a review of the factorial-desigu studies[ J]. J Clin Hypertens (Greenwich) ,2004,6: 569 -577.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部